Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note released on Tuesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 0.3 %

EGRX opened at $3.74 on Tuesday. The firm’s 50 day moving average is $4.74 and its 200-day moving average is $5.73. Eagle Pharmaceuticals has a 52-week low of $3.50 and a 52-week high of $23.52. The firm has a market capitalization of $48.58 million, a P/E ratio of 3.17 and a beta of 0.46.

Institutional Trading of Eagle Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio acquired a new position in shares of Eagle Pharmaceuticals in the third quarter worth about $145,000. Allspring Global Investments Holdings LLC grew its position in shares of Eagle Pharmaceuticals by 11.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 191,635 shares of the specialty pharmaceutical company’s stock worth $3,022,000 after buying an additional 20,204 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Eagle Pharmaceuticals by 66.5% in the third quarter. Assenagon Asset Management S.A. now owns 217,668 shares of the specialty pharmaceutical company’s stock worth $3,433,000 after buying an additional 86,917 shares during the last quarter. Smith Graham & Co. Investment Advisors LP increased its stake in shares of Eagle Pharmaceuticals by 1.4% in the third quarter. Smith Graham & Co. Investment Advisors LP now owns 273,099 shares of the specialty pharmaceutical company’s stock worth $4,307,000 after buying an additional 3,648 shares during the last quarter. Finally, Headlands Technologies LLC raised its holdings in Eagle Pharmaceuticals by 263.4% in the third quarter. Headlands Technologies LLC now owns 2,326 shares of the specialty pharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,686 shares in the last quarter. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.